As drug modalities grow more complex, low bioburden powders for reconstitution are emerging as a critical strategy to ensure sterility, stability, and scalability.
Christine Allen, CEO and Co-Founder of Intrepid Labs, and Andy Lewis, CSO at Quotient Sciences, highlight their strategic partnership to accelerate drug product development with AI and ML technologies.
At Kindeva, we Manufacture More Tomorrows™ for patients worldwide. With best in-class facilities and comprehensive CDMO services, we provide more than manufacturing – we deliver strategic value. Our global network of 10 manufacturing and R&D sites offer exceptional integrated knowledge and capabilities, including Annex 1-compliant state-of-the-art aseptic fill finish capacity and next-generation sustainable inhalation propellant technology. By combining expertise in injectable, pulmonary, nasal, and dermal drug delivery, we help meet the demands of today and deliver the possibilities of tomorrow.
Pace® makes the world a safer, healthier place. We advance the science of our pharmaceutical and biopharmaceutical customers through the drug development process, from early-phase R&D through clinical trials and GMP commercial product support. For customers with in-house manufacturing and labs, we provide support through professional services.
